Effectiveness of Sofosbuvir-Based Therapy in Chronic Hepatitis C Patients: A Clinical Study from Abbottabad, KPK Pakistan
DOI:
https://doi.org/10.63521/pjg.42.1.2026.29Keywords:
Hepatitis C, Sofosbuvir, HCV RNA PCR, SVR, Pakistan, DAAsAbstract
Hepatitis C Virus (HCV) infection is a significant public health issue in Pakistan. Direct acting antivirals (DAAs) particularly sofosbuvir based regimens have demonstrated high efficacy in achieving sustained virologic response (SVR). This observational study included 350 patients diagnosed with chronic hepatitis HCV infection between July 2024 to september 2025.
Among 350 patients 190 were male and 160 were female age ranges from 16 to 68 years. After PCR all patients were put on sofosbuvir 400 mg for 12 weeks. Out of 190 male patients 175 (92%) achieved SVR12 while 152 (95 %) female achieved SVR12 after 12 weeks treatment.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr saifullah khan (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the Pakistan Journal of Gastroenterology (PJG) the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
